Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. 

Factors such as the rising number of hematopoietic stem cell transplants is expected to fuel the market growth during the forecast period.

For instance, according to the Center for International Blood and Marrow Transplant Research Transplant Activity Report, the number of peripheral blood hematopoietic cell transplants (HCTs) performed in the U.S. were as follows:

DISEASE CATEGORY

2015

2016

2017

Acute lymphoblastic leukemia (ALL)

1,322

1,314

1,430

Acute myelogenous leukemia (AML)

3,264

3,359

3,365

Multiple myeloma (MM)

6,970

7,507

7,722

Total

21,487

21,839

22,863

The global hematopoietic stem cell transplantation market is estimated to be valued at US$ 2,092.6 million in 2020 and is expected to exhibit a CAGR of 11.2% during the forecast period (2020-2027).

Figure 1: Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%) Analysis, By Transplant Type, 2020

Hematopoietic Stem Cell Transplantation (HSCT)  | Coherent Market Insights

Rising incidence of leukemia and lymphoma is driving the growth of the global hematopoietic stem cell transplantation market.

The increasing prevalence of leukemia and lymphoma is expected to drive the hematopoietic stem cell transplantation market growth during the forecast period.

As per the 2019 report by Leukemia and Lymphoma Society, an estimated 176,200 individuals in the U.S. were diagnosed with leukemia, lymphoma or myeloma and approximately 1,399,180 individuals were living with leukemia, lymphoma or myeloma. The increasing incidence rate is expected to drive demand for hematopoietic stem cell transplantation, thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market.

According to the World Cancer Research Fund 2018 report, one third of the cancer cases (globally) occur in economically developed economies such as the U.S. and Europe owing to lack of physical activity, obesity, and/or poor nutrition. Furthermore, around 90% of leukemia occurs in the middle age and develops with aging.

request-sample

Hematopoietic Stem Cell Transplantation (HSCT) Markett Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 2,092.6 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 11.2% 2027 Value Projection: US$ 4,391.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Transplant Type: Allogeneic, Autologous
  • By Indication: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Other Non-Malignant Disorders
  • By Application: Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT)
Companies covered:

Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc. and Stempeutics Research Pvt Ltd.

Growth Drivers:
  • Rising incidence of leukemia and lymphoma
  • Strategic collaboration between key players
Restraints & Challenges:
  • Side Effect Of Hematopoietic Stem Cell Transplantation Procedures

Hematopoietic Stem Cell Transplantation (HSCT) Market- Restraints

Side effects of hematopoietic stem cell transplantation on organs and body parts such as gastrointestinal tract, mouth, heart, lungs which are associated with the conditioning regimen and others and serious complication of graft vs. host disease are expected to slow down the growth of the hematopoietic stem cell transplantation market.

Graft-versus-host disease (GVHD) is the complication of standard allogeneic and reduced-intensity allogeneic stem cell transplantations which occurs when the graft view the patient’s healthy cells (the host) as foreign, and attack and damage them. A close HLA match between the donor and patient helps to lower the risk of GVHD, but it does not eliminate it. Graft-versus-host disease can be mild, moderate, or severe. In some cases, it can be life-threatening.

Hematopoietic Stem Cell Transplantation (HSCT) Market– Regional Analysis

North America accounted for the largest share in the hematopoietic stem cell transplantation market owing to the increasing incidence of leukemia, lymphoma, or myeloma. For instance, according to the Leukemia and Lymphoma Society, an estimated 172,910 people in the U.S. were diagnosed with leukemia, lymphoma or myeloma in 2017, thus leading to increasing adoption of stem cells for its efficient treatment.

Asia Pacific is expected to witness the fastest growth during the forecast period owing to rising number of HSCT transplants in the region. For instance, according to the Japanese Data Center for Hematopoietic Cell Transplantation, the number of transplants in Japan were as follows:

Hematopoietic Stem Cell Transplantation (HSCT)  | Coherent Market Insights

Figure 3: Hematopoietic Stem Cell Transplantation (HSCT) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Hematopoietic Stem Cell Transplantation (HSCT)  | Coherent Market Insights

Hematopoietic Stem Cell Transplantation (HSCT) Market- Competitive Landscape

Key players operating in the Hematopoietic Stem Cell Transplantation (HSCT) Market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources; 1) autologous, that uses stem cells from the patient’s own body, 2) and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.

Market Dynamics

The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma. According to Center for Disease Control and Prevention (CDC), in the U.S., around 45,360 people were diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). According to the same source the condition is more prevalent among men than women. Leukemia accounts for around 3% of all new cancer cases.

Key features of the study:

  • This report provides in-depth analysis of the global hematopoietic stem cell transplantation market, market size (US$ Mn), and compound annual growth rate (CAGR %) for the forecast period 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hematopoietic stem cell transplantation market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global hematopoietic stem cell transplantation market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the hematopoietic stem cell transplantation market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type:
    • Allogeneic
    • Autologous
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication:
    • Acute Myeloid Leukemia (AML)
    • Acute Lymphoblastic Leukemia (ALL)
    • Hodgkin lymphoma (HL)
    • Non-Hodgkin Lymphoma (NHL)
    • Multiple Myeloma (MM)
    • Other Non-Malignant Disorders
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application:
    • Bone Marrow Transplant (BMT)
    • Peripheral Blood Stem Cells Transplant (PBSCT)
    • Cord Blood Transplant (CBT)
  • Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication:
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Other Non-Malignant Disorders
      • By Application:
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication:
        • Acute Myeloid Leukaemia (AML)
        • Acute Lymphoblastic Leukaemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Other Non-Malignant Disorders
      • By Application:
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication:
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Other Non-Malignant Disorders
      • By Application:
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication:
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Other Non-Malignant Disorders
      • By Application:
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication:
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Other Non-Malignant Disorders
      • By Application:
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Transplant Type:
        • Allogeneic
        • Autologous
      • By Indication:
        • Acute Myeloid Leukemia (AML)
        • Acute Lymphoblastic Leukemia (ALL)
        • Hodgkin lymphoma (HL)
        • Non-Hodgkin Lymphoma (NHL)
        • Multiple Myeloma (MM)
        • Other Non-Malignant Disorders
      • By Application:
        • Bone Marrow Transplant (BMT)
        • Peripheral Blood Stem Cells Transplant (PBSCT)
        • Cord Blood Transplant (CBT)
  • Company Profiles
    • Pluristem Therapeutics Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • CellGenix GmbH
    • Regen Biopharma Inc.
    • Lonza Group
    • Kiadis Pharma
    • Taiga Biotechnologies, Inc.
    • Takeda Pharmaceutical Company Limited
    • Escape Therapeutics, Inc.
    • Bluebird Bio
    • Talaris Therapeutics, Inc.
    • Marker Therapeutics Inc.
    • Stempeutics Research Pvt Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Transplant Type
      • Market Snippet, By Indication
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Pipeline Analysis
    • PEST Analysis
    • Reimbursement Scenario
    • Regulatory Scenario
    • Epidemiology
    • Government Initiatives
    • Treatment Algorithm
  4. Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Guidelines for COVID-19 Management in Hematopoietic Stem Cell Transplantation (HSCT)
    • Impact of COVID-19 on Clinical Trials
  5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Autologous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Allogeneic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Acute Myeloid Leukemia (AML)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Acute Lymphoblastic Leukemia (ALL)
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hodgkin lymphoma (HL)
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Non-Hodgkin Lymphoma (NHL)
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Multiple Myeloma (MM)
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Other Non-malignant Disorders
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Bone Marrow Transplant (BMT)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Peripheral Blood Stem Cells Transplant (PBSCT)
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Cord Blood Transplant (CBT)
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Transplant Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Transplant Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Latin America
      • Market Size and Forecast, By Transplant Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Asia Pacific
      • Market Size and Forecast, By Transplant Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Transplant Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Transplant Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Company Profiles
      • Pluristem Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • CellGenix GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Regen Biopharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Lonza Group
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Kiadis Pharma
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Taiga Biotechnologies, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Escape Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bluebird Bio
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Talaris Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Marker Therapeutics Inc. 
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Stempeutics Research Pvt Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 33 figures on "Global Hematopoietic Stem Cell Transplantation (HSCT) Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the Hematopoietic Stem Cell Transplantation (HSCT) Market is expected to be 11.2% during the forecast period (2020-2027).
The value of the Market is estimated to be US$ 2,092.6 million in 2020.
The prominent players in the global Hematopoietic Stem Cell Transplantation (HSCT) Market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc. and Stempeutics Research Pvt Ltd.
The market is expected to be valued at US$ 4,391.0 Mn in 2027.
North America is the major region in the market.
Rising incidence of leukemia and lymphoma and strategic collaboration between key players are expected to drive growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner